- Home
- SUI vs RPRX Comparison
SUI vs RPRX Comparison
Compare SUI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUI
- RPRX
- Stock Information
- Founded
- SUI 1975
- RPRX 1996
- Country
- SUI United States
- RPRX United States
- Employees
- SUI N/A
- RPRX N/A
- Industry
- SUI Real Estate Investment Trusts
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- SUI Real Estate
- RPRX Health Care
- Exchange
- SUI Nasdaq
- RPRX Nasdaq
- Market Cap
- SUI 17.1B
- RPRX 14.2B
- IPO Year
- SUI 1993
- RPRX 2020
- Fundamental
- Price
- SUI $130.24
- RPRX $31.37
- Analyst Decision
- SUI Buy
- RPRX Strong Buy
- Analyst Count
- SUI 10
- RPRX 5
- Target Price
- SUI $136.60
- RPRX $41.60
- AVG Volume (30 Days)
- SUI 846.0K
- RPRX 4.2M
- Earning Date
- SUI 04-28-2025
- RPRX 05-08-2025
- Dividend Yield
- SUI 2.90%
- RPRX 2.81%
- EPS Growth
- SUI N/A
- RPRX N/A
- EPS
- SUI 0.71
- RPRX 1.91
- Revenue
- SUI $3,190,400,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- SUI N/A
- RPRX $33.46
- Revenue Next Year
- SUI $2.50
- RPRX $4.44
- P/E Ratio
- SUI $183.46
- RPRX $16.41
- Revenue Growth
- SUI 0.81
- RPRX N/A
- 52 Week Low
- SUI $110.98
- RPRX $24.05
- 52 Week High
- SUI $147.83
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- SUI 50.68
- RPRX 35.44
- Support Level
- SUI $127.01
- RPRX $32.26
- Resistance Level
- SUI $131.47
- RPRX $34.14
- Average True Range (ATR)
- SUI 3.07
- RPRX 0.76
- MACD
- SUI -0.37
- RPRX -0.29
- Stochastic Oscillator
- SUI 61.45
- RPRX 11.78
About SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 666 properties, which includes 350 manufactured housing communities, 179 residential vehicle communities, and 137 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.